Vascular disrupting agent drug classes differ in effects on the cytoskeleton.
Vascular disrupting agents (VDAs), anti-cancer drugs that target established tumor blood vessels, fall into two main classes: microtubule targeting drugs, exemplified by combretastatin A4 (CA4), and flavonoids, exemplified by 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Both classes increase permea...
Main Authors: | Sujeong Kim, Leonid Peshkin, Timothy J Mitchison |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3404093?pdf=render |
Similar Items
-
Vascular aging, the vascular cytoskeleton and aortic stiffness
by: Lova Prasadareddy Kajuluri, et al.
Published: (2021-06-01) -
Signaling Mechanisms and Disrupted Cytoskeleton in the Diphenyl Ditelluride Neurotoxicity
by: Regina Pessoa-Pureur, et al.
Published: (2014-01-01) -
Sinularin, an Anti-Cancer Agent Causing Mitochondria-Modulated Apoptosis and Cytoskeleton Disruption in Human Hepatocellular Carcinoma
by: Chou-Yuan Ko, et al.
Published: (2021-04-01) -
Microtubule cytoskeleton-disrupting activity of MWCNTs: applications in cancer treatment
by: Lorena García Hevia, et al.
Published: (2020-12-01) -
Cytoskeleton-disrupting agent cytochalasin B reduces oxidative stress caused by high glucose in the human arterial smooth muscle
by: Kazumi Takaishi, et al.
Published: (2020-12-01)